Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone. NAME Edaravone (Radicava)
APPROVED FOR

Amyotrophic lateral sclerosis
TYPE
Small molecule
MOLECULAR TARGETS
Antioxidant. Edaravone is thought to be a free radical scavenger, and it reportedly eliminates lipid peroxides and hydroxyl radicals
CELLULAR TARGETS
The mechanism in ALS is uncertain. The drug presumably works to mitigate oxidative injury in CNS neurons, principally motor neurons at risk for degeneration in ALS. Data to support this physiology is not comprehensive, and the drug company officially indicates that the mechanism is "unknown."
EFFECTS ON TARGETS
The drug clinically acts to slow disease progression as measured by functional rating scales 
